Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study

Title: Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study
Authors: Fallico M.; Avitabile T.; Castellino N.; Longo A.; Russo A.; Bonfiglio V.; Parisi F.; Furino C.; Panozzo G.; Scorcia V.; Carnevali A.; Bandello F.; Parodi M. B.; Cennamo G.; Cillino S.; Vadala M.; Sunseri Trapani V.; Cagini C.; Fiore T.; Lupidi M.; Parravano M.; Varano M.; Giorno P.; Boscia F.; Giancipoli E.; Eandi C.; Le Mer Y.; Reibaldi M.
Contributors: Fallico, M.; Avitabile, T.; Castellino, N.; Longo, A.; Russo, A.; Bonfiglio, V.; Parisi, F.; Furino, C.; Panozzo, G.; Scorcia, V.; Carnevali, A.; Bandello, F.; Parodi, M. B.; Cennamo, G.; Cillino, S.; Vadala, M.; Sunseri Trapani, V.; Cagini, C.; Fiore, T.; Lupidi, M.; Parravano, M.; Varano, M.; Giorno, P.; Boscia, F.; Giancipoli, E.; Eandi, C.; Le Mer, Y.; Reibaldi, M.
Publication Year: 2021
Collection: IRIS Università degli Studi di Napoli Federico II
Subject Terms: cataract surgery; dexamethasone implant; diabete; diabetic macular oedema
Description: Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT central subfield (CSF) thickness ≥20% compared to baseline. The primary outcomes were anatomical and functional results at 3 months. Results: Two hundred twenty-one patients were included: 136 in the ‘precataract DEX’ group and 85 in the ‘concomitant treatments’ group. At 3 months, a reduction of CSF thickness ≥ 20% was found in 7.3% of eyes in the ‘precataract DEX group’ and in 83.7% of eyes in the ‘concomitant treatments’ group (p < 0.001), with mean CSF thickness lower in the latter group (371 ± 52 μm versus 325 ± 57 μm, p < 0.001). At 3 months, mean best-corrected visual acuity had improved from baseline in both groups (p < 0.001), with no difference between groups (p = 0. 20). No serious systemic adverse events were reported. Conclusion: Both approaches prevented a worsening of DME, showing a comparable visual outcome. Dexamethasone (DEX) implant given at the same time as cataract surgery provided a better anatomical outcome.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000543140200001; volume:99; issue:1; firstpage:74; lastpage:80; numberofpages:7; journal:ACTA OPHTHALMOLOGICA; https://hdl.handle.net/11588/820569
DOI: 10.1111/aos.14516
Availability: https://hdl.handle.net/11588/820569; https://doi.org/10.1111/aos.14516
Rights: info:eu-repo/semantics/openAccess ; license:Dominio pubblico ; license uri:http://creativecommons.org/publicdomain/zero/1.0/
Accession Number: edsbas.B7566254
Database: BASE